US20090026075A1 - Electrochemical Analyte Detection Apparatus and Method - Google Patents
Electrochemical Analyte Detection Apparatus and Method Download PDFInfo
- Publication number
- US20090026075A1 US20090026075A1 US12/179,446 US17944608A US2009026075A1 US 20090026075 A1 US20090026075 A1 US 20090026075A1 US 17944608 A US17944608 A US 17944608A US 2009026075 A1 US2009026075 A1 US 2009026075A1
- Authority
- US
- United States
- Prior art keywords
- analyte
- electrodes
- test reagent
- redox
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/4166—Systems measuring a particular property of an electrolyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
Definitions
- This application relates to an apparatus and method for electrochemical detection of an analyte in a sample.
- the invention utilizes a specific binding relationship between the analyte and at least one reagent provided in the apparatus as a means for detecting the analyte.
- the present invention provides a new method and apparatus for electrochemical detection of analyte in a sample that makes use of a binding interaction.
- the invention relies on the discovery that asymmetric distribution of a redox enzyme between two electrodes that occurs when a redox enzyme-containing reagent is immobilized at the surface of one electrode can be detected as a chemical potential gradient arising from an asymmetry in the distribution of oxidized or reduced redox substrate.
- This chemical potential gradient can be detected potentiometrically by observing the potential difference between the electrodes in an open circuit, or amperometrically by observing the current flow between the electrodes when the circuit is closed. In both cases, the observation of asymmetry can be done without the application of an external potential or current to the electrodes.
- a sandwich type assay is utilized.
- a sample to be tested for analyte is introduced to a test cell in the presence of a mobile test reagent.
- the test cell comprises a first and a second electrode.
- the first electrode has immobilized on the surface thereof an immobilized test reagent.
- the mobile test reagent comprises an analyte-binding portion and a redox enzyme portion, and the immobilized test reagent comprises an analyte binding portion.
- analyte is present in the sample in the test cell, at least a portion of the mobile test reagent becomes immobilized on the first electrode thereby creating an asymmetry in redox enzyme concentration between the first and second electrodes when analyte is present.
- a redox substrate for the redox enzyme in the test cell is also supplied. The redox substrate is acted upon (oxidized or reduced) by the redox enzyme. If there is an asymmetry in redox enzyme concentration between the first and second electrodes (i.e. when analyte is present in the sample), this results in a chemical potential gradient between the first and second electrodes. This chemical potential gradient is detected to determine analyte in the sample. In this embodiment, the greater the asymmetry and the resulting potential gradient, the greater the amount of analyte in the sample.
- a competition or displacement type of assay is utilized.
- the redox enzyme is coupled to analyte or an analog of the analyte that can bind to a common immobilized test reagent.
- the redox enzyme is provided already bound to the electrode via the immobilized test reagent.
- FIGS. 1A and B show schematic representations of reduced mediator distribution between two electrodes when redox enzyme distribution is asymmetric ( FIG. 1 A) or asymmetric ( FIG. 1B ).
- FIGS. 2A and B illustrate the determination of asymmetric enzyme distribution at two electrodes using amperometry.
- FIG. 3 shows a sandwich assay format useful in the present invention.
- FIGS. 4 and 5 shows competition/displacement assay format useful in the present invention.
- FIGS. 6A-C shows construction of a test cell with facing electrodes.
- FIGS. 7A-C show examples of side-by-side electrode configurations.
- FIG. 8 shows an external view of a meter in accordance with the invention.
- FIG. 9 shows a circuit usable in the meter of the invention.
- FIG. 10 shows potential difference in open circuit as a function of time for different levels of asymmetry in enzyme distribution between two electrodes.
- FIG. 11 shows current in short circuit as a function of time for different levels of asymmetry in enzyme distribution between two electrodes.
- FIG. 12 shows the correlation of peak potential difference with ratio of electrode enzyme activities
- FIG. 13 shows the correlation of peak current with ratio of electrode enzyme activities
- FIG. 14 shows a schematic plot of a known total enzyme E t on x-axis and measured I 300 on the y-axis.
- FIG. 15 shows a schematic plot of a known E t on x-axis and measured I 300 on the v-axis.
- FIG. 16 shows a plot of how log(R) affects the slope of I 0 versus E t which is used to derive parameters a and b.
- FIG. 17 shows a plot of log(R) affects the intercept of I 0 versus E t which is used to derive parameters c and d.
- FIG. 18 shows the correlation between the actual amount of an enzyme and the estimated amount of enzyme as determined in accordance with the invention.
- analyte refers to a material of interest that may be present in a sample.
- Analytes that are detectable in the present invention are those that can be associated in a specific-binding interaction with at least one other reagent to that they can participate in a sandwich, competition or displacement assay configuration as described herein.
- Examples of analytes include antigens or haptens such as peptides (for example hormones), proteins (for example, enzymes), drugs, pesticides, microorganisms, antibodies, and nucleic acids that can participate in sequence specific hybridization reactions with a complementary sequence.
- analyte-specific enzyme component or reagent refers to a reagent that includes both an analyte-binding portion and a redox enzyme portion.
- An analyte-specific enzyme component is suitably used as a mobile reagent.
- (c) “determination of an analyte” refers to qualitative, semi-quantitative and quantitative processes for evaluating a sample. In a qualitative evaluation, a result indicates whether or not analyte was detected in the sample. In a semi-quantitative evaluation, the result indicates whether or not analyte is present above some pre-defined threshold. In a quantitative evaluation, the result is a numerical indication of the amount of analyte present.
- redox enzyme refers to an enzyme that oxidizes or reduces a substrate. Such enzymes may generally be known as oxidases, peroxidases, reductases, or dehydrogenases. Enzymes such as glucose oxidase, and various peroxidases are commonly used in the analytical devices, and therefore the preparation of these enzymes in stable form is well known.
- the term “redox substrate” refers to a compound or combination of compounds that interact with the redox enzyme to produce a chemical potential gradient.
- the enzyme substrate may directly produce a redox active species sufficient to create the chemical potential gradient.
- a secondary compound may be needed.
- the interaction with glucose to produce gluconolactone and reduced enzyme produces the chemical potential gradient when the reduced enzyme is oxidized by a mediator compound, which is the actual redox active species in the chemical potential gradient.
- the “redox substrate” is the combination of the substrate compound glucose and the mediator compound.
- the term “chemical potential gradient” refers to a concentration gradient of a redox active species. It will be appreciated that more rigorously, the potential gradient arises from a gradient in the ratio of reduced to oxidized species between the electrodes, however, the idea of a concentration gradient of one species is more easily visualized and is therefore used here. When such a gradient is present between two electrodes, a potential difference is detectable if the circuit is opened, and a current will flow until the gradient dissipates when the circuit is closed. It will be appreciated that the chemical potential gradient is transient in the devices of the invention, and that the distribution of the redox active species will even out over time, when new redox active species stops being created.
- the term “chemical potential gradient” as used herein refers only to this transient gradient that arises from the asymmetry of the distribution of redox enzyme and not to any potential gradient that arises from the application of a potential difference or current flow between the electrodes.
- the phrase “detecting the chemical potential gradient between the first and second electrodes” refers to the detection of the chemical potential gradient in either an open or a closed circuit, using either potentiometric or amperometric measurements.
- enzyme activity and “enzyme concentration” are used as equivalent terms herein, although it will be appreciated that in ordinary usage they may have different meanings.
- Activity of an enzyme provides a quantitative measure of the catalytic capability of an enzyme. This depends not only on the physical amount of the enzyme present in the volume (i.e. the concentration), but also on the conditions which affect the catalytic efficiency of the enzyme.
- the present invention actually measures asymmetry in enzyme activity, since the presence of inactive enzyme will not produce an asymmetry in redox substrate. However, since it is desirable to control the quality of the enzyme and the conditions, this is in effect also a measurement of asymmetry in enzyme concentration.
- the term “immobilized on the first electrode” refers to immobilization directly or indirectly on the surface of the electrode, provided that the material immobilized becomes immobilized in volume associated with the first electrode and closer to the first electrode than the second electrode.
- the enzyme is considered to be “immobilized on” the electrode even though there are several intervening moieties in the sandwich.
- the term “immobilized test reagent” refers to the component of a sandwich or competition/displacement reaction that is associated with an electrode when performing the assay of the invention. Immobilization may be through the formation of a chemical bond (covalent or non-covalent) between the immobilized test reagent and the surface of the electrode, or it may be a physical association as through the placement of the immobilized test reagent within a gel or membrane disposed on the surface of the electrode.
- the immobilized test reagent comprises a binding moiety which interacts with analyte to produce a change in the distribution of the redox enzyme (as part of the analyte-binding enzyme component) when analyte is present in a sample.
- the immobilized reagent will be immobilized during initial manufacture of the test apparatus. In other embodiments, immobilization will occur in situ after addition of the sample.
- immobilized test reagent refers to any circumstance in which the structure:
- FIGS. 1A and B show schematic representations of reduced mediator distribution between two electrodes ( 1 , 2 ) when redox enzyme distribution is asymmetric ( FIG. 1 A) or asymmetric ( FIG. 1B ).
- the equations above can be used to quantitate the ratio of concentrations of enzyme at two electrodes 1 and 2 using potentiometry.
- the two electrodes are connected in open circuit, and the potential difference between them is measured. If enzyme 3 is more active or concentrated at one electrode than the other (i.e., it has an asymmetric distribution as shown in FIG. 1A ), the concentration of reduced mediator will be higher at that electrode than the other, giving rise to a electrical potential difference between the electrodes.
- the asymmetric distribution of enzyme activity will result in an asymmetric distribution of reduced mediator, that can be observed by following current when the potential difference between the electrodes is forced to zero by closing the circuit between them. If reduced mediator is generated by enzyme activity and diffuses to an electrode, current will flow and sufficient mediator will be reoxidized, such that the reduced mediator concentration is equal at both electrodes. The current flow will be proportional to the difference in flux of reduced mediator to the two electrodes.
- FIGS. 2A and B illustrate the use of these principles to quantify the ratio of concentrations of enzyme at two electrodes, using amperometry.
- the two electrodes are connected in short circuit, and the current flowing between them is measured.
- mediator will be reduced or oxidized at the electrodes when necessary to maintain an equal chemical potential at each electrode.
- reduced mediator is oxidized at one electrode, current will flow and an equivalent quantity of oxidized mediator will be reduced at the other electrode. If the enzyme activity at each electrode is equal, no electron transfer will be necessary to keep the chemical potentials balanced, so no current will flow. If more enzyme activity is present at one electrode than the other, reduced mediator will be consumed at that electrode and produced at the other electrode to maintain a balanced chemical potential, and current will flow.
- the theory of the present invention is applicable to the practical application of determining analytes in a sample. This can be done in various binding formats.
- two analyte-specific chemical components are utilized, and these are selected in to correspond to the analyte to be determined.
- Table 1 Various non-limiting combinations are set forth in Table 1.
- Analyte Analyte receptor binding component of Analyte-specific enzyme disease-specific disease associated- antibody that antibody, for example antigen, such as recognizes human an antibody to peptide epitope found antibodies, influenza, disease on an influenza of aptamers causing organism interest, aptamers amplified nucleic nucleic acid nucleic acid sequence acid sequence complementary to the complementary including a suspected target to the known primer suspected target and a known primer hormone hormone receptor, hormone receptor, apatamer or antibody apatamer or antibody drug drug receptor, hormone receptor, aptamer or antibody apatamer or antibody pesticides pesticide binding pesticide binding proteins, aptamers, proteins, apatmers antibodies to pesticides antibodies that recognize the antibodies to pesticides
- the “antibody” incorporated in the device can be a complete antibody such as an immunoglobulin, or it may be a engineered binding portion of an antibody such as a single-chain antibody (scFv) or Domain Antibodies (dAb) as described at www.domantis.com.
- Immunoassays for drugs are described in U.S. Pat. Nos. 7,220,842, 5,677,132 and 5,618,926.
- Immunoassays for pesticides and pesticide degradation products are described in U.S. Pat. No. 6,635,434.
- Drug and hormone receptors may be native hormone receptors, or they may be engineered species with similar binding properties as are known in the art. (See U.S. Pat. Nos.
- the components of the reaction are combined in such a way that they result in a difference in distribution symmetry of the redox enzyme that is dependent on the presence or absence of analyte in a sample.
- Various device formats can achieve this result.
- FIG. 3 shows two electrodes 31 and 32 .
- Electrode 31 has analyte-specific receptors 33 immobilized on the interior surface thereof.
- Analyte 34 associates with the analyte specific receptors 33 .
- an analyte-specific enzyme reagent 35 which associates with analyte in such as way that the activity of the enzyme is maintained in the bound and the unbound state, and a redox substrate 36 , 36 ′. Capture of the analyte-specific enzyme reagent 35 occurs at the surface of electrode 31 when analyte 34 is present because of the formation of receptor 33 -analyte 34 -analyte-specific enzyme species 35 sandwich.
- the activity of the enzyme results in an increased concentration of one form of the redox substrate (in the case of FIG. 3 , of form 36 ) near electrode 31 and hence a detectable chemical potential gradient whose magnitude is related to the amount of analyte develops.
- the sandwich does not form and thus no detectable chemical potential gradient is produced.
- FIGS. 4 and 5 show a competition format for an assay device in accordance with the invention.
- the sample cell is defined by two electrodes 41 , 42 .
- Electrode 41 has analyte-receptors 43 disposed thereon.
- the redox enzyme 45 comprises the enzyme coupled to an analyte or an analyte mimetic. In the absence of analyte, as shown in FIG. 4 , redox enzyme 45 is coupled to analyte receptor 43 , resulting in an asymmetry in the distribution of the redox enzyme. Additional redox enzyme 45 ′ may be present in the bulk of the sample depending on the amount of redox enzyme, analyte receptors and the affinity of the analyte receptors for the redox enzyme.
- analyte 44 when analyte 44 is present, it competes with redox enzyme 45 for the analyte receptor 43 , resulting in the displacement of at least some of the redox enzyme 45 from the analyte receptors 43 , creating a less asymmetric distribution of the redox enzyme and thus the ability to determine analyte in a sample.
- FIGS. 6A-C show a sample cell for a device in accordance with the invention, constructed using facing electrodes.
- the device is formed from a top layer 61 and bottom layer 62 , each having a conductive surface ( 61 ′, 62 ′) facing the interior of the device, and an insulating spacer layer 63 .
- Contacts 64 and 65 extend from the top layer 61 and bottom layer 62 to allow contact with the conductive surfaces for either potentiometric or amperometric measurements.
- the conductive layer 63 has an opening therein that together with the facing conductive surfaces 61 ′ and 62 ′ defines a sample cell.
- This sample cell is open to the exterior for introduction of sample, for example through an opening 66 at the end device as shown in FIG. 6C .
- Various structures for forming cells of this type, with multiple openings and/or vent holes are known in the art for example as the particular design of the cell is not critical to the practicing of the present invention.
- other designs for connectors are known, and this also is not critical to the practicing of the present invention.
- one of the conductive surfaces ( 61 ′ or 62 ′) has the analyte receptor (immobilized test reagent) disposed thereon.
- the remainder of the reagents for determination of analyte may be disposed within the sample cell as a dried reagent layer 67 , or may be added to the sample prior to introduction to the sample cell.
- the sample cell portion as shown in FIGS. 6A-C is generally constructed as a single use, disposable component.
- the first and electrodes may be disposed on the same surface within the sample cell.
- This configuration is referred to herein as side-by-side electrodes.
- FIGS. 7A-C show non-limiting examples of configurations that can be used for side-by-side configurations, including parallel strips ( FIG. 7A ), interdigitated strips ( 7 B) and concentric rings ( FIG. 7C ).
- asymmetry in redox enzyme distribution between one electrode 71 and the other electrode 72 results in a measurable chemical potential gradient between the two electrodes.
- sample cell portions as shown in FIGS. 7A-C are generally constructed as a single use, disposable component.
- the device of the invention has a means for communicating the observed potential or current to a user in a meaningful way indicative of the determination of analyte. This can range from a simple qualitative result (analyte present or not present), or to a specific numerical value for the amount of analyte. The sophistication of the communication means varies accordingly.
- the device may have at a visible location a spot of a material that changes color in response to the passage of current or the application of the potential difference created by an asymmetry above a threshold level.
- the device does not need a separate meter portion, and may be simply a disposable test strip with an indicator spot on the outside.
- sample cell will be contained within a disposable test strip that is inserted into a reusable meter.
- the meter will contain the electronics for measuring the potential difference or current at a defined period of time after introduction of a sample or test strip, and for conversion of the measured value to a displayed value. This conversion may make use of a look-up table that converts specific value of current or potential to values of analyte depending on the calibration values for the specific device geometry and analyte.
- FIG. 8 shows an external view of a meter in accordance with the invention.
- the meter has a housing 81 having a display 82 and one or more control interfaces 83 (for example power buttons, or scroll wheels etc).
- the housing has a slot 84 for receiving a test device.
- circuitry Internal to the housing 81 is circuitry for applying a potential or current to the electrodes of the test device when a sample is applied. This may be done following an initialization signal from a user, or following an automated detection of test device insertion and sample application.
- Suitable circuits usable in the meter of the invention are known in the art, for example from US Patent Publication No. US 2005-0265094 A1, which is incorporated herein by reference.
- One such circuit is shown in FIG. 9 .
- an ideal voltmeter 942 is provided which can measure the potential across the electrodes 941 , 938 .
- Switch 944 is provided which is opened when the potential is to be measured or closed for measurement of current. When open the cell 939 is “floating” as to at least one of its electrodes, permitting a voltage measurement that is unaffected by signals at the amplifier 935 .
- the switch 944 may be a mechanical switch (e.g. a relay) or an FET (field-effect transistor) switch, or a solid-state switch. In a simple case the switch opens to an open circuit; more generally it could open to a very high resistance.
- This circuit can be used to measure either a potential difference or a current difference.
- other circuits including much simpler and more complicated circuits can be used to achieve application of either or both of a potential difference or a current.
- the circuit of FIG. 9 can also be used to apply a potential difference to the test device of the invention. While, as discussed above, such application of potential is not required to perform the measurement of the invention, application of potential prior to the measurement (particularly in a test device with facing electrode construction) can result in a more rapid measurement time by effectively driving analyte and/or analyte-binding enzyme component towards the electrode with the immobilized reagent using what is in essence electrophoresis, provided that the analyte or analyte-binding enzyme component is charged under the conditions (particularly pH) found within the test device. A step function or a sine wave passing from negative to positive potential differences could also effect something similar to washing in situ within the test device.
- the present invention provides the ability to perform binding assays for the detection of analyte with electrochemical detection, without the need to apply an external potential or current, and without the need for washing steps commonly employed in sandwich immunoassay procedures. Because of this, the apparatus used to perform the assay can be much simpler, easy to use, and less expensive. In addition, the device components in an electrochemical assay are more robust than those used for example in optical measurements, facilitating the manufacture of the low cost reusable meter for use with disposable test devices.
- the present invention can make use of small samples of blood, tears, saliva, or sweat, with minimal invasiveness to the subject. (samples of less than 10 ul, preferably less than 1 ul are particularly desirable for blood tests). Further, the present invention can provide for very rapid test times. Common immunoassay procedures take up to an hour or more.
- the small volume of the test devices of the invention and the sensitivity of the test to small differences in the distribution of the enzyme means that shorter times (for example less the 30 minutes, more preferably less than 10 minutes, and most preferably less than 1 minute) are accessible depending on the concentration of analyte to be measured and the binding kinetics of the analyte with the binding elements of the mobile and immobilized reagents.
- endogenous glucose can be used as a component of the redox substrate in a glucose oxidase-based system when the sample is a blood sample.
- An electrochemical cell test strip comprising two gold electrodes separated by a double-sided adhesive layer was constructed using the method described in US Patent Publication No. US-2005-0258035-A1 which is incorporated herein by reference.
- An total of 100 nL enzyme solution (27 mg/mL glucose oxidase in 100 mM sodium citrate buffer pH: 4.1) was dispensed onto the two electrodes and allowed to dry.
- Test strips were made with different ratios of electrode enzyme activity by apportioning the 100 nL enzyme solution between the two electrodes, with the balance made up with water.
- FIG. 12 shows that peak potential difference attained correlated with the ratio of enzyme activity dispensed on each electrode.
- FIG. 13 shows that peak current attained correlated with the ratio of enzyme activity dispensed on each electrode.
- the amount of enzyme (E1) present at one electrode can be determined independent of the amount (E2) present at the other electrode.
- Test strips containing a range of 0.25 microgram to 1 microgram of glucose oxidase were made, with the enzyme distributed between the two electrodes such that R was between 1.5 and 19. These strips were made by dispensing a solution of 0.25 microgram to 1 microgram glucose oxidase in 100 nL of 100 mM sodium citrate buffer pH 4.1 onto electrode 1 ; and a solution of 0 to 0.4 microgram glucose oxidase in 100 nL of 100 mM sodium citrate buffer pH 4.1 onto electrode 2 , then allowing the dispensed solutions to dry.
- FIG. 14 shows a schematic of known total enzyme E t on the x-axis and measured I 300 on the y-axis.
- E t total enzyme
- I 300 measured on the y-axis.
- the relationship between E t and I 300 can be established from this plot, for example the data can be represented by the equation
- FIG. 15 shows a schematic plot of a known E t on x-axis and measured I 0 on the y-axis. As shown, a family of lines is generated, one for each value of the ratio R. From FIG. 15 , the linear relationship of the I 0 current vs E t is dependent on R, i.e.
- I 0 ( a log R+b ) ⁇ E t +( c log R+d )
- E1 can be calculated as follows:
- FIG. 18 shows calculated values of E 1 versus actual values of E 1 , for strips with varying amounts of enzyme on the two electrodes.
- FIG. 18 indicates that our estimated values for the enzyme dispensed on one electrode correlated well with the actual amount that was dispensed, and were independent of the amount of enzyme dispensed on the other electrode.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 60/952,099 filed Jul. 26, 2007, which application is incorporated herein by reference for all purposes.
- This application relates to an apparatus and method for electrochemical detection of an analyte in a sample. The invention utilizes a specific binding relationship between the analyte and at least one reagent provided in the apparatus as a means for detecting the analyte.
- Analysis methods in which specific binding between an analyte and a reagent forms the basis for the assay are known. For example, in enzyme-linked immunoassay (EIA or ELISA) procedures, a sandwich is formed between an immobilized antibody and a mobile enzyme-antibody reagent when analyte is present through the interaction of the analyte with the antibody components. This results in the immobilization of the enzyme. The subsequent detection of immobilized enzyme is therefore indicative the presence of analyte in a test solution. (See U.S. Pat. Nos. 3,654,090, 4,169,012, and 4,642,285) Similar sandwich assays are used in chromatographic immunoassays where a colored tag (for example a colored latex bead) on the mobile reagent becomes trapped on a substrate at a defined location to produce a pattern that indicates the presence of analyte in a sample. (See U.S. Pat. Nos. 4,943,522, 5,656,503, 5,712,172 and 5,766,961) Analysis methods that depend on specific binding between an analyte and a reagent may also take the form of competition assays, in which the formation of a complex involving a labeled reagent is inhibited in the presence of analyte in an analyte-concentration dependent mariner (See U.S. Pat. Nos. 4,868,131, 5,981,2798 and 5,989,921), or displacement assays in which a pre-existing complex involving a labeled reagent is disrupted in the presence of analyte in an analyte-concentration dependent manner. (See U.S. Pat. Nos. 4,746,631 and 6,020,209).
- Immunoassays in which detection of the analyte depends on an electrochemical measurement are also known. U.S. Pat. No. 5,149,630 discloses an assay in which the extent to which the transfer of electrons between an enzyme substrate and an electrode, associated with the substrate reaction, is perturbed by complex formation or by displacement of any ligand complex relative to unbound enzyme-labelled component. This determination is made in the presence of an applied potential. An applied potential is also used to measure current in the assay device disclosed in U.S. Pat. Nos. 5,198,367, 5,427,912. U.S. Pat. No. 5,494,831 discloses the application of a current and the measurement of changes in impedance that result in binding.
- The present invention provides a new method and apparatus for electrochemical detection of analyte in a sample that makes use of a binding interaction. The invention relies on the discovery that asymmetric distribution of a redox enzyme between two electrodes that occurs when a redox enzyme-containing reagent is immobilized at the surface of one electrode can be detected as a chemical potential gradient arising from an asymmetry in the distribution of oxidized or reduced redox substrate. This chemical potential gradient can be detected potentiometrically by observing the potential difference between the electrodes in an open circuit, or amperometrically by observing the current flow between the electrodes when the circuit is closed. In both cases, the observation of asymmetry can be done without the application of an external potential or current to the electrodes.
- In a first embodiment of the invention, a sandwich type assay is utilized. In this embodiment, a sample to be tested for analyte is introduced to a test cell in the presence of a mobile test reagent. The test cell comprises a first and a second electrode. The first electrode has immobilized on the surface thereof an immobilized test reagent. The mobile test reagent comprises an analyte-binding portion and a redox enzyme portion, and the immobilized test reagent comprises an analyte binding portion. If analyte is present in the sample in the test cell, at least a portion of the mobile test reagent becomes immobilized on the first electrode thereby creating an asymmetry in redox enzyme concentration between the first and second electrodes when analyte is present. A redox substrate for the redox enzyme in the test cell is also supplied. The redox substrate is acted upon (oxidized or reduced) by the redox enzyme. If there is an asymmetry in redox enzyme concentration between the first and second electrodes (i.e. when analyte is present in the sample), this results in a chemical potential gradient between the first and second electrodes. This chemical potential gradient is detected to determine analyte in the sample. In this embodiment, the greater the asymmetry and the resulting potential gradient, the greater the amount of analyte in the sample.
- In a second embodiment of the invention, a competition or displacement type of assay is utilized. In this assay, the redox enzyme is coupled to analyte or an analog of the analyte that can bind to a common immobilized test reagent. Optionally the redox enzyme is provided already bound to the electrode via the immobilized test reagent. When sample is added, analyte present in the sample will compete with the redox enzyme for the binding sites provided by the immobilized test reagent resulting in a reduction in the amount of asymmetry that would occur is all of the binding sites were occupied by redox enzyme.
-
FIGS. 1A and B show schematic representations of reduced mediator distribution between two electrodes when redox enzyme distribution is asymmetric (FIG. 1 A) or asymmetric (FIG. 1B ). -
FIGS. 2A and B illustrate the determination of asymmetric enzyme distribution at two electrodes using amperometry. -
FIG. 3 shows a sandwich assay format useful in the present invention. -
FIGS. 4 and 5 shows competition/displacement assay format useful in the present invention. -
FIGS. 6A-C shows construction of a test cell with facing electrodes. -
FIGS. 7A-C show examples of side-by-side electrode configurations. -
FIG. 8 shows an external view of a meter in accordance with the invention. -
FIG. 9 shows a circuit usable in the meter of the invention. -
FIG. 10 shows potential difference in open circuit as a function of time for different levels of asymmetry in enzyme distribution between two electrodes. -
FIG. 11 shows current in short circuit as a function of time for different levels of asymmetry in enzyme distribution between two electrodes. -
FIG. 12 shows the correlation of peak potential difference with ratio of electrode enzyme activities -
FIG. 13 shows the correlation of peak current with ratio of electrode enzyme activities -
FIG. 14 shows a schematic plot of a known total enzyme Et on x-axis and measured I300 on the y-axis. -
FIG. 15 shows a schematic plot of a known Et on x-axis and measured I300 on the v-axis. -
FIG. 16 shows a plot of how log(R) affects the slope of I0 versus Et which is used to derive parameters a and b. -
FIG. 17 shows a plot of log(R) affects the intercept of I0 versus Et which is used to derive parameters c and d. -
FIG. 18 shows the correlation between the actual amount of an enzyme and the estimated amount of enzyme as determined in accordance with the invention. - As used in the specification and claims of this application, the following definitions should be applied:
- (a) “analyte” refers to a material of interest that may be present in a sample. Analytes that are detectable in the present invention are those that can be associated in a specific-binding interaction with at least one other reagent to that they can participate in a sandwich, competition or displacement assay configuration as described herein. Examples of analytes include antigens or haptens such as peptides (for example hormones), proteins (for example, enzymes), drugs, pesticides, microorganisms, antibodies, and nucleic acids that can participate in sequence specific hybridization reactions with a complementary sequence.
- (b) “analyte-specific enzyme component” or reagent refers to a reagent that includes both an analyte-binding portion and a redox enzyme portion. An analyte-specific enzyme component is suitably used as a mobile reagent.
- (c) “determination of an analyte” refers to qualitative, semi-quantitative and quantitative processes for evaluating a sample. In a qualitative evaluation, a result indicates whether or not analyte was detected in the sample. In a semi-quantitative evaluation, the result indicates whether or not analyte is present above some pre-defined threshold. In a quantitative evaluation, the result is a numerical indication of the amount of analyte present.
- (d) the term “redox enzyme” refers to an enzyme that oxidizes or reduces a substrate. Such enzymes may generally be known as oxidases, peroxidases, reductases, or dehydrogenases. Enzymes such as glucose oxidase, and various peroxidases are commonly used in the analytical devices, and therefore the preparation of these enzymes in stable form is well known.
- (e) the term “redox substrate” refers to a compound or combination of compounds that interact with the redox enzyme to produce a chemical potential gradient. In some cases, the enzyme substrate may directly produce a redox active species sufficient to create the chemical potential gradient. In others, a secondary compound may be needed. For example, in the case of glucose oxidase, the interaction with glucose to produce gluconolactone and reduced enzyme produces the chemical potential gradient when the reduced enzyme is oxidized by a mediator compound, which is the actual redox active species in the chemical potential gradient. Thus, in this case the “redox substrate” is the combination of the substrate compound glucose and the mediator compound.
- (f) the term “chemical potential gradient” refers to a concentration gradient of a redox active species. It will be appreciated that more rigorously, the potential gradient arises from a gradient in the ratio of reduced to oxidized species between the electrodes, however, the idea of a concentration gradient of one species is more easily visualized and is therefore used here. When such a gradient is present between two electrodes, a potential difference is detectable if the circuit is opened, and a current will flow until the gradient dissipates when the circuit is closed. It will be appreciated that the chemical potential gradient is transient in the devices of the invention, and that the distribution of the redox active species will even out over time, when new redox active species stops being created. The term “chemical potential gradient” as used herein refers only to this transient gradient that arises from the asymmetry of the distribution of redox enzyme and not to any potential gradient that arises from the application of a potential difference or current flow between the electrodes.
- (g) the phrase “detecting the chemical potential gradient between the first and second electrodes” refers to the detection of the chemical potential gradient in either an open or a closed circuit, using either potentiometric or amperometric measurements.
- (h) the terms “enzyme activity” and “enzyme concentration” are used as equivalent terms herein, although it will be appreciated that in ordinary usage they may have different meanings. Activity of an enzyme provides a quantitative measure of the catalytic capability of an enzyme. This depends not only on the physical amount of the enzyme present in the volume (i.e. the concentration), but also on the conditions which affect the catalytic efficiency of the enzyme. The present invention actually measures asymmetry in enzyme activity, since the presence of inactive enzyme will not produce an asymmetry in redox substrate. However, since it is desirable to control the quality of the enzyme and the conditions, this is in effect also a measurement of asymmetry in enzyme concentration.
- (i) the term “immobilized on the first electrode” refers to immobilization directly or indirectly on the surface of the electrode, provided that the material immobilized becomes immobilized in volume associated with the first electrode and closer to the first electrode than the second electrode. For example, in the case of the formation of an electrode-antibody-analyte-antibody-enzyme sandwich, the enzyme is considered to be “immobilized on” the electrode even though there are several intervening moieties in the sandwich.
- (j) the term “immobilized test reagent” refers to the component of a sandwich or competition/displacement reaction that is associated with an electrode when performing the assay of the invention. Immobilization may be through the formation of a chemical bond (covalent or non-covalent) between the immobilized test reagent and the surface of the electrode, or it may be a physical association as through the placement of the immobilized test reagent within a gel or membrane disposed on the surface of the electrode. The immobilized test reagent comprises a binding moiety which interacts with analyte to produce a change in the distribution of the redox enzyme (as part of the analyte-binding enzyme component) when analyte is present in a sample. In some embodiments, the immobilized reagent will be immobilized during initial manufacture of the test apparatus. In other embodiments, immobilization will occur in situ after addition of the sample. Thus, the term immobilized test reagent refers to any circumstance in which the structure:
-
- electrode-(link)n-reagent with binding site for analyte
is obtained, where n is 0 or an integer of 1 or greater. The latter option allows production of one set of generic devices in which the linking agent is not analyte specific, with the addition of reagent that binds to the link and the analyte for any given analyte-specific test. This additional reagent could be added to the test strip at manufacture, or to the sample prior to application to the test device.
- electrode-(link)n-reagent with binding site for analyte
- For convenience, the theoretical basis for the invention will be discussed in the context of glucose oxidase as the redox enzyme and a combination of glucose and a mediator as the redox substrate. Nothing in this discussion should be taken as an indication, however, that the invention is limited to use with these materials.
- In common glucose measurement systems, enzyme present in the sample cell oxidizes glucose to gluconolactone, and the enzyme is reduced. Oxidized mediator (for example ferricyanide) reacts with the reduced enzyme to regenerate the oxidized form of the enzyme, and produce reduced mediator. This process continues until either glucose or oxidized mediator is exhausted. If the enzyme is distributed asymmetrically within the sample cell, then the production of reduced mediator is also asymmetric, and the resulting asymmetry, in the distribution of reduced mediator persists for a period of time (determined by diffusion parameters) even after exhaustion of the limiting reagent.
- When reduced mediator is present in a solution between two electrodes, the potential difference between the two electrodes is given by the Nernst equation
-
- where E is the potential difference between
electrodes -
-
FIGS. 1A and B show schematic representations of reduced mediator distribution between two electrodes (1, 2) when redox enzyme distribution is asymmetric (FIG. 1 A) or asymmetric (FIG. 1B ). The equations above can be used to quantitate the ratio of concentrations of enzyme at twoelectrodes enzyme 3 is more active or concentrated at one electrode than the other (i.e., it has an asymmetric distribution as shown inFIG. 1A ), the concentration of reduced mediator will be higher at that electrode than the other, giving rise to a electrical potential difference between the electrodes. If equal activity or concentrations of enzyme are present at both electrodes (i.e., it has a symmetric distribution as shown inFIG. 1B ), the concentration of reduced mediator at each electrode will be equal, and the electrodes will be at equal electrical potential and the measured potential difference will be 0. - If, instead of potentiometry, the electrodes are connected in short-circuit, the asymmetric distribution of enzyme activity will result in an asymmetric distribution of reduced mediator, that can be observed by following current when the potential difference between the electrodes is forced to zero by closing the circuit between them. If reduced mediator is generated by enzyme activity and diffuses to an electrode, current will flow and sufficient mediator will be reoxidized, such that the reduced mediator concentration is equal at both electrodes. The current flow will be proportional to the difference in flux of reduced mediator to the two electrodes.
-
FIGS. 2A and B illustrate the use of these principles to quantify the ratio of concentrations of enzyme at two electrodes, using amperometry. The two electrodes are connected in short circuit, and the current flowing between them is measured. As electrical potential difference between the electrodes is constrained to zero, mediator will be reduced or oxidized at the electrodes when necessary to maintain an equal chemical potential at each electrode. As reduced mediator is oxidized at one electrode, current will flow and an equivalent quantity of oxidized mediator will be reduced at the other electrode. If the enzyme activity at each electrode is equal, no electron transfer will be necessary to keep the chemical potentials balanced, so no current will flow. If more enzyme activity is present at one electrode than the other, reduced mediator will be consumed at that electrode and produced at the other electrode to maintain a balanced chemical potential, and current will flow. - The theory of the present invention is applicable to the practical application of determining analytes in a sample. This can be done in various binding formats. In general, two analyte-specific chemical components are utilized, and these are selected in to correspond to the analyte to be determined. In general, it is desired to have at least one of the components (generally the analyte-receptor) be highly specific for the analyte while the other component can be less specific in its binding. Various non-limiting combinations are set forth in Table 1.
-
Analyte Analyte receptor binding component of Analyte- specific enzyme disease-specific disease associated- antibody that antibody, for example antigen, such as recognizes human an antibody to peptide epitope found antibodies, influenza, disease on an influenza of aptamers causing organism interest, aptamers amplified nucleic nucleic acid nucleic acid sequence acid sequence complementary to the complementary including a suspected target to the known primer suspected target and a known primer hormone hormone receptor, hormone receptor, apatamer or antibody apatamer or antibody drug drug receptor, hormone receptor, aptamer or antibody apatamer or antibody pesticides pesticide binding pesticide binding proteins, aptamers, proteins, apatmers antibodies to pesticides antibodies that recognize the antibodies to pesticides - As will be understood in the art, the “antibody” incorporated in the device can be a complete antibody such as an immunoglobulin, or it may be a engineered binding portion of an antibody such as a single-chain antibody (scFv) or Domain Antibodies (dAb) as described at www.domantis.com. Immunoassays for drugs are described in U.S. Pat. Nos. 7,220,842, 5,677,132 and 5,618,926. Immunoassays for pesticides and pesticide degradation products are described in U.S. Pat. No. 6,635,434. Drug and hormone receptors may be native hormone receptors, or they may be engineered species with similar binding properties as are known in the art. (See U.S. Pat. Nos. 7,214,511, and 6,806,359, Rasmussen et al, J. Biol. Chem., Vol. 276, Issue 7, 4717-4723, Feb. 16, 2001). US Patent Publication 20050130208 discloses a cocaine-specific aptamer that could be used as a binding portion of an analyte-specific enzyme component or as an immobilized test reagent. Other aptmers are listed on the database of the Ellington research group at http://aptamer.icmb.utexas.edu/. Enzyme-aptamer coupling has been described by Mir et al. “Different Strategies To Develop an Electrochemical Thrombin Aptasensor.” Electrochemical Communication 8 (9006): 505-511.
- The components of the reaction are combined in such a way that they result in a difference in distribution symmetry of the redox enzyme that is dependent on the presence or absence of analyte in a sample. Various device formats can achieve this result.
- A. Sandwich Format
-
FIG. 3 shows twoelectrodes Electrode 31 has analyte-specific receptors 33 immobilized on the interior surface thereof.Analyte 34 associates with the analytespecific receptors 33. Also present is an analyte-specific enzyme reagent 35 which associates with analyte in such as way that the activity of the enzyme is maintained in the bound and the unbound state, and aredox substrate specific enzyme reagent 35 occurs at the surface ofelectrode 31 whenanalyte 34 is present because of the formation of receptor 33-analyte 34-analyte-specific enzyme species 35 sandwich. The activity of the enzyme results in an increased concentration of one form of the redox substrate (in the case ofFIG. 3 , of form 36) nearelectrode 31 and hence a detectable chemical potential gradient whose magnitude is related to the amount of analyte develops. When the analyte is not present, the sandwich does not form and thus no detectable chemical potential gradient is produced. - B. Competition/Displacement Format
-
FIGS. 4 and 5 show a competition format for an assay device in accordance with the invention. The sample cell is defined by twoelectrodes Electrode 41 has analyte-receptors 43 disposed thereon. Theredox enzyme 45 comprises the enzyme coupled to an analyte or an analyte mimetic. In the absence of analyte, as shown inFIG. 4 ,redox enzyme 45 is coupled toanalyte receptor 43, resulting in an asymmetry in the distribution of the redox enzyme.Additional redox enzyme 45′ may be present in the bulk of the sample depending on the amount of redox enzyme, analyte receptors and the affinity of the analyte receptors for the redox enzyme. As shown inFIG. 5 , whenanalyte 44 is present, it competes withredox enzyme 45 for theanalyte receptor 43, resulting in the displacement of at least some of theredox enzyme 45 from theanalyte receptors 43, creating a less asymmetric distribution of the redox enzyme and thus the ability to determine analyte in a sample. - C. Device Construction—Sample Cell with Facing Electrodes
-
FIGS. 6A-C show a sample cell for a device in accordance with the invention, constructed using facing electrodes. The device is formed from atop layer 61 andbottom layer 62, each having a conductive surface (61′, 62′) facing the interior of the device, and an insulatingspacer layer 63.Contacts top layer 61 andbottom layer 62 to allow contact with the conductive surfaces for either potentiometric or amperometric measurements. As shown inFIG. 6B , theconductive layer 63 has an opening therein that together with the facingconductive surfaces 61′ and 62′ defines a sample cell. This sample cell is open to the exterior for introduction of sample, for example through anopening 66 at the end device as shown inFIG. 6C . Various structures for forming cells of this type, with multiple openings and/or vent holes are known in the art for example as the particular design of the cell is not critical to the practicing of the present invention. Similarly, other designs for connectors are known, and this also is not critical to the practicing of the present invention. - In an embodiment of the device of the invention, one of the conductive surfaces (61′ or 62′) has the analyte receptor (immobilized test reagent) disposed thereon. The remainder of the reagents for determination of analyte may be disposed within the sample cell as a dried
reagent layer 67, or may be added to the sample prior to introduction to the sample cell. - The sample cell portion as shown in
FIGS. 6A-C is generally constructed as a single use, disposable component. - D. Device Construction—Side-by-Side Electrodes
- In addition to facing electrodes as discussed above, the first and electrodes may be disposed on the same surface within the sample cell. This configuration is referred to herein as side-by-side electrodes.
FIGS. 7A-C show non-limiting examples of configurations that can be used for side-by-side configurations, including parallel strips (FIG. 7A ), interdigitated strips (7B) and concentric rings (FIG. 7C ). In each case, asymmetry in redox enzyme distribution between oneelectrode 71 and theother electrode 72 results in a measurable chemical potential gradient between the two electrodes. - The sample cell portions as shown in
FIGS. 7A-C are generally constructed as a single use, disposable component. - E. Device Construction—Communication of Results
- In addition to the sample cell, the device of the invention has a means for communicating the observed potential or current to a user in a meaningful way indicative of the determination of analyte. This can range from a simple qualitative result (analyte present or not present), or to a specific numerical value for the amount of analyte. The sophistication of the communication means varies accordingly.
- In one embodiment of the invention, to provide a qualitative result, the device may have at a visible location a spot of a material that changes color in response to the passage of current or the application of the potential difference created by an asymmetry above a threshold level. In this case, the device does not need a separate meter portion, and may be simply a disposable test strip with an indicator spot on the outside.
- More commonly the sample cell will be contained within a disposable test strip that is inserted into a reusable meter. The meter will contain the electronics for measuring the potential difference or current at a defined period of time after introduction of a sample or test strip, and for conversion of the measured value to a displayed value. This conversion may make use of a look-up table that converts specific value of current or potential to values of analyte depending on the calibration values for the specific device geometry and analyte.
-
FIG. 8 shows an external view of a meter in accordance with the invention. As shown, the meter has ahousing 81 having adisplay 82 and one or more control interfaces 83 (for example power buttons, or scroll wheels etc). The housing has aslot 84 for receiving a test device. Internal to thehousing 81 is circuitry for applying a potential or current to the electrodes of the test device when a sample is applied. This may be done following an initialization signal from a user, or following an automated detection of test device insertion and sample application. - Suitable circuits usable in the meter of the invention are known in the art, for example from US Patent Publication No. US 2005-0265094 A1, which is incorporated herein by reference. One such circuit is shown in
FIG. 9 . InFIG. 9 , anideal voltmeter 942 is provided which can measure the potential across theelectrodes Switch 944 is provided which is opened when the potential is to be measured or closed for measurement of current. When open thecell 939 is “floating” as to at least one of its electrodes, permitting a voltage measurement that is unaffected by signals at theamplifier 935. Theswitch 944 may be a mechanical switch (e.g. a relay) or an FET (field-effect transistor) switch, or a solid-state switch. In a simple case the switch opens to an open circuit; more generally it could open to a very high resistance. - This circuit can be used to measure either a potential difference or a current difference. As will be appreciated by persons skilled in the art, other circuits, including much simpler and more complicated circuits can be used to achieve application of either or both of a potential difference or a current.
- The circuit of
FIG. 9 can also be used to apply a potential difference to the test device of the invention. While, as discussed above, such application of potential is not required to perform the measurement of the invention, application of potential prior to the measurement (particularly in a test device with facing electrode construction) can result in a more rapid measurement time by effectively driving analyte and/or analyte-binding enzyme component towards the electrode with the immobilized reagent using what is in essence electrophoresis, provided that the analyte or analyte-binding enzyme component is charged under the conditions (particularly pH) found within the test device. A step function or a sine wave passing from negative to positive potential differences could also effect something similar to washing in situ within the test device. - The present invention provides the ability to perform binding assays for the detection of analyte with electrochemical detection, without the need to apply an external potential or current, and without the need for washing steps commonly employed in sandwich immunoassay procedures. Because of this, the apparatus used to perform the assay can be much simpler, easy to use, and less expensive. In addition, the device components in an electrochemical assay are more robust than those used for example in optical measurements, facilitating the manufacture of the low cost reusable meter for use with disposable test devices.
- The present invention can make use of small samples of blood, tears, saliva, or sweat, with minimal invasiveness to the subject. (samples of less than 10 ul, preferably less than 1 ul are particularly desirable for blood tests). Further, the present invention can provide for very rapid test times. Common immunoassay procedures take up to an hour or more. The small volume of the test devices of the invention and the sensitivity of the test to small differences in the distribution of the enzyme means that shorter times (for example less the 30 minutes, more preferably less than 10 minutes, and most preferably less than 1 minute) are accessible depending on the concentration of analyte to be measured and the binding kinetics of the analyte with the binding elements of the mobile and immobilized reagents.
- Depending on the nature of the sample and the redox substrate, it may be possible to use materials from the sample as part of the reaction system. For example, endogenous glucose can be used as a component of the redox substrate in a glucose oxidase-based system when the sample is a blood sample.
- In the following examples, the utility and operability of the invention are demonstrated using a model system in which enzyme is coated onto the surface of one of two electrodes in an electrode pair. This model does not require the capture of the enzyme, and therefore is useful for modeling the after-capture behavior with a limited number of variables, although it does not provide a full picture of the binding kinetics of an actual test system. Capture of enzyme using reagents in other enzyme sandwich, competition and displacement assays and the like is well known.
- An electrochemical cell test strip comprising two gold electrodes separated by a double-sided adhesive layer was constructed using the method described in US Patent Publication No. US-2005-0258035-A1 which is incorporated herein by reference. An total of 100 nL enzyme solution (27 mg/mL glucose oxidase in 100 mM sodium citrate buffer pH: 4.1) was dispensed onto the two electrodes and allowed to dry. Test strips were made with different ratios of electrode enzyme activity by apportioning the 100 nL enzyme solution between the two electrodes, with the balance made up with water. For example to make strips with 75% enzyme activity on
electrode 1 and 25% enzyme activity onelectrode electrode electrode 2. A solution of 100 mM beta-D-glucose and 100 mM potassium ferricyanide in water was added to the electrochemical cell. The potential difference in open circuit (FIG. 10 ), or current in short circuit (FIG. 11 ), was recorded. It is noted that the period of time required to achieve clear differences in the signal at the different levels of asymmetry is short (less than 15 seconds) thus making the invention suitable for rapid measurement. -
FIG. 12 shows that peak potential difference attained correlated with the ratio of enzyme activity dispensed on each electrode.FIG. 13 shows that peak current attained correlated with the ratio of enzyme activity dispensed on each electrode. - By combining the determination of the ratio of enzyme activity dispensed on each electrode (as in Example 1) with a determination of total enzyme activity, the amount of enzyme (E1) present at one electrode can be determined independent of the amount (E2) present at the other electrode.
- Varying amounts of enzyme were dispensed on 2 surfaces that served as electrodes in a sandwich configuration as described in Example 1. Ratio of enzyme activity present at the two electrodes (R=E1/E2) was determined by measurement of the current flowing in a short circuit configuration. Then the total enzyme activity (Et=E1+E2) was determined by measuring the current flowing with an applied potential difference. E1 and E2 were then calculated from the determined values of R and Et.
- Test strips containing a range of 0.25 microgram to 1 microgram of glucose oxidase were made, with the enzyme distributed between the two electrodes such that R was between 1.5 and 19. These strips were made by dispensing a solution of 0.25 microgram to 1 microgram glucose oxidase in 100 nL of 100 mM sodium citrate buffer pH 4.1 onto
electrode 1; and a solution of 0 to 0.4 microgram glucose oxidase in 100 nL of 100 mM sodium citrate buffer pH 4.1 ontoelectrode 2, then allowing the dispensed solutions to dry. - A solution of 100 mM beta-D-glucose and 100 mM potassium ferricyanide in water was added to the electrochemical cell and current in short circuit was recorded for 5 seconds. Following this, 300 mV was applied for 10 s. The current immediately prior to 5 s was averaged to give I0 and the current immediately prior to 15 s was averaged to give I300 (i.e. the measured I at 5 s is I0 and measured I at 15 s was designated as I300).
- Measured I (both I0 and I300) for increasing amounts of Et each with a variable ratio R, was recorded and plotted.
-
FIG. 14 shows a schematic of known total enzyme Et on the x-axis and measured I300 on the y-axis. The relationship between Et and I300 can be established from this plot, for example the data can be represented by the equation -
I 300 =m×E t +n - where m and n are the slope and intercept of the line.
-
FIG. 15 shows a schematic plot of a known Et on x-axis and measured I0 on the y-axis. As shown, a family of lines is generated, one for each value of the ratio R. FromFIG. 15 , the linear relationship of the I0 current vs Et is dependent on R, i.e. -
I 0 =f(E t,log R) - To further establish this function, we plotted known log(R) vs slope (
FIG. 16 ) for each line shown inFIG. 15 . In addition, as shown inFIG. 17 we plotted known log(R) and intercept for each line inFIG. 15 . - Thus the function f can further be defined as the relationship
-
I 0=(a log R+b)×E t+(c log R+d) - The parameters a and b can be calculated from the plots in
FIG. 16 and the parameters c and d fromFIG. 17 . Once the parameters a, b, c, d, m and n have been determined, E1 can be calculated as follows: - 1. Calculate Et from I300
-
E t=(I 300 −n)÷m. - 2. Calculate R from I0 and Et
-
log R=(I 0 −b×E t −d)÷(a×E t +c) -
R=10log R - 3. Calculate E1 from Et and R
-
E 1=(R×E t)÷(1+R) -
FIG. 18 shows calculated values of E1 versus actual values of E1, for strips with varying amounts of enzyme on the two electrodes.FIG. 18 indicates that our estimated values for the enzyme dispensed on one electrode correlated well with the actual amount that was dispensed, and were independent of the amount of enzyme dispensed on the other electrode.
Claims (24)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/179,446 US20090026075A1 (en) | 2007-07-26 | 2008-07-24 | Electrochemical Analyte Detection Apparatus and Method |
US15/017,787 US9939440B2 (en) | 2007-07-26 | 2016-02-08 | Electrochemical analyte detection apparatus and method |
US15/944,148 US20180231552A1 (en) | 2007-07-26 | 2018-04-03 | Electrochemical Analyte Detection Apparatus and Method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95209907P | 2007-07-26 | 2007-07-26 | |
US12/179,446 US20090026075A1 (en) | 2007-07-26 | 2008-07-24 | Electrochemical Analyte Detection Apparatus and Method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/017,787 Continuation US9939440B2 (en) | 2007-07-26 | 2016-02-08 | Electrochemical analyte detection apparatus and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090026075A1 true US20090026075A1 (en) | 2009-01-29 |
Family
ID=40281828
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/179,446 Abandoned US20090026075A1 (en) | 2007-07-26 | 2008-07-24 | Electrochemical Analyte Detection Apparatus and Method |
US15/017,787 Active 2028-10-28 US9939440B2 (en) | 2007-07-26 | 2016-02-08 | Electrochemical analyte detection apparatus and method |
US15/944,148 Abandoned US20180231552A1 (en) | 2007-07-26 | 2018-04-03 | Electrochemical Analyte Detection Apparatus and Method |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/017,787 Active 2028-10-28 US9939440B2 (en) | 2007-07-26 | 2016-02-08 | Electrochemical analyte detection apparatus and method |
US15/944,148 Abandoned US20180231552A1 (en) | 2007-07-26 | 2018-04-03 | Electrochemical Analyte Detection Apparatus and Method |
Country Status (8)
Country | Link |
---|---|
US (3) | US20090026075A1 (en) |
EP (2) | EP2584044B1 (en) |
KR (1) | KR101532064B1 (en) |
CN (2) | CN101802612B (en) |
AU (1) | AU2008279042B2 (en) |
CA (1) | CA2694045C (en) |
HK (1) | HK1184196A1 (en) |
WO (1) | WO2009015291A1 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060178688A1 (en) * | 2001-06-12 | 2006-08-10 | Dominique Freeman | Tissue penetration device |
US20090192411A1 (en) * | 2002-04-19 | 2009-07-30 | Dominique Freeman | Method and apparatus for penetrating tissue |
US7875047B2 (en) | 2002-04-19 | 2011-01-25 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7901365B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909775B2 (en) | 2001-06-12 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7909774B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909777B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7914465B2 (en) | 2002-04-19 | 2011-03-29 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7988645B2 (en) | 2001-06-12 | 2011-08-02 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US8007446B2 (en) | 2002-04-19 | 2011-08-30 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8062231B2 (en) | 2002-04-19 | 2011-11-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8079960B2 (en) | 2002-04-19 | 2011-12-20 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8197421B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8251921B2 (en) | 2003-06-06 | 2012-08-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8262614B2 (en) | 2003-05-30 | 2012-09-11 | Pelikan Technologies, Inc. | Method and apparatus for fluid injection |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US8296918B2 (en) | 2003-12-31 | 2012-10-30 | Sanofi-Aventis Deutschland Gmbh | Method of manufacturing a fluid sampling device with improved analyte detecting member configuration |
US8333710B2 (en) | 2002-04-19 | 2012-12-18 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8382682B2 (en) | 2002-04-19 | 2013-02-26 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8435190B2 (en) | 2002-04-19 | 2013-05-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8439872B2 (en) | 1998-03-30 | 2013-05-14 | Sanofi-Aventis Deutschland Gmbh | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8721671B2 (en) | 2001-06-12 | 2014-05-13 | Sanofi-Aventis Deutschland Gmbh | Electric lancet actuator |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102409359A (en) * | 2011-11-22 | 2012-04-11 | 中国铝业股份有限公司 | Online measuring device and method for alumina concentration in aluminum electrolytic cell |
EP2657347A1 (en) | 2012-04-26 | 2013-10-30 | Université Paris Diderot - Paris 7 | Electrochemical competitive assay and use thereof |
CN110609139B (en) * | 2018-06-14 | 2023-06-30 | 深圳市理邦精密仪器股份有限公司 | Antigen concentration excess detection method, device and storage medium |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
US4169012A (en) * | 1976-09-24 | 1979-09-25 | Akzona Incorporated | Stabilized peroxidase reagent for enzyme immunoassay |
US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
US4746631A (en) * | 1985-05-09 | 1988-05-24 | Ultra Diagnostics Corporation | Immunoassay method, device, and test kit |
US4868131A (en) * | 1986-07-11 | 1989-09-19 | Fuji Photo Film Co., Ltd. | Competitive binding immunoassay process |
US4943522A (en) * | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US5149630A (en) * | 1984-01-26 | 1992-09-22 | Forrest Gordon C | Methods of assay |
US5198367A (en) * | 1989-06-09 | 1993-03-30 | Masuo Aizawa | Homogeneous amperometric immunoassay |
US5413690A (en) * | 1993-07-23 | 1995-05-09 | Boehringer Mannheim Corporation | Potentiometric biosensor and the method of its use |
US5427912A (en) * | 1993-08-27 | 1995-06-27 | Boehringer Mannheim Corporation | Electrochemical enzymatic complementation immunoassay |
US5494831A (en) * | 1993-08-30 | 1996-02-27 | Hughes Aircraft Company | Electrochemical immunosensor system and methods |
US5618926A (en) * | 1989-03-10 | 1997-04-08 | Hoffmann-La Roche Inc. | Immunoassay reagents |
US5656503A (en) * | 1987-04-27 | 1997-08-12 | Unilever Patent Holdings B.V. | Test device for detecting analytes in biological samples |
US5677132A (en) * | 1971-05-20 | 1997-10-14 | Strahilevitz; Meir | Immunological assay reagent package |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US5712172A (en) * | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
US5766961A (en) * | 1991-01-11 | 1998-06-16 | Quidel Corporation | One-step lateral flow nonbibulous assay |
US5981298A (en) * | 1995-12-13 | 1999-11-09 | Surmodics, Inc. | Immunoassay device and method |
US5989921A (en) * | 1988-06-27 | 1999-11-23 | Carter Wallace, Inc. | Test device and method for colored particle immunoassay |
US6020209A (en) * | 1997-04-28 | 2000-02-01 | The United States Of America As Represented By The Secretary Of The Navy | Microcapillary-based flow-through immunosensor and displacement immunoassay using the same |
US20020090738A1 (en) * | 1988-11-14 | 2002-07-11 | I-Stat Corporation | System and method of microdispensing and arrays of biolayers provided by same |
US6478938B1 (en) * | 2000-05-24 | 2002-11-12 | Bio Digit Laboratories Corporation | Electrochemical membrane strip biosensor |
US20030143598A1 (en) * | 2001-11-09 | 2003-07-31 | Viswanadham Garimella | Bioconjugate-nanoparticle probes |
US6635434B1 (en) * | 1999-09-17 | 2003-10-21 | Exiqon A/S | Immunoassay for pesticides and their degradation products |
US6806359B1 (en) * | 1986-10-24 | 2004-10-19 | The Salk Institute For Biological Studies | Hormone receptor compositions and methods |
US20040245101A1 (en) * | 2001-08-29 | 2004-12-09 | Itamar Willner | Self-powered biosensor |
US20050130208A1 (en) * | 2002-04-19 | 2005-06-16 | The Trustees Of Columbia University | Displacement assay for detection of small molecules |
US20050258035A1 (en) * | 2004-05-21 | 2005-11-24 | Agamatrix, Inc. | Electrochemical Cell and Method of Making an Electrochemical Cell |
US20050265094A1 (en) * | 2004-05-30 | 2005-12-01 | Agamatrix, Inc. | Measuring device and methods for use therewith |
US20060160100A1 (en) * | 2005-01-19 | 2006-07-20 | Agency For Science, Technology And Research | Enzymatic electrochemical detection assay using protective monolayer and device therefor |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4003194A1 (en) | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | Electrochemical determn. of analytes - using oxido-reductase and substance of being reduced, which is re-oxidised on the electrode |
IL108726A (en) * | 1994-02-22 | 1999-12-31 | Yissum Res Dev Co | Electrobiochemical method and system for the determination of an analyte which is a member of a recognition pair in a liquid medium and electrodes therefor |
CN1204398C (en) * | 2001-05-15 | 2005-06-01 | 松下电器产业株式会社 | Biosensor |
WO2002103343A1 (en) | 2001-06-14 | 2002-12-27 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US20030175828A1 (en) | 2002-03-15 | 2003-09-18 | Lazar James G. | Signal amplification by Hybrid Capture |
CN1447114A (en) * | 2003-02-14 | 2003-10-08 | 李伟 | Method for testing bioactive substance by using electrochemistry process with oxido-reductase marked and its device |
MXPA06001914A (en) * | 2003-08-21 | 2006-05-31 | Agamatrix Inc | Method and apparatus for assay of electrochemical properties. |
-
2008
- 2008-07-24 US US12/179,446 patent/US20090026075A1/en not_active Abandoned
- 2008-07-24 CA CA2694045A patent/CA2694045C/en active Active
- 2008-07-24 KR KR1020107004269A patent/KR101532064B1/en active IP Right Grant
- 2008-07-24 CN CN200880108191.6A patent/CN101802612B/en active Active
- 2008-07-24 WO PCT/US2008/071073 patent/WO2009015291A1/en active Application Filing
- 2008-07-24 EP EP12199820.7A patent/EP2584044B1/en active Active
- 2008-07-24 CN CN201610575436.2A patent/CN106442961B/en active Active
- 2008-07-24 EP EP08782340A patent/EP2174135B1/en active Active
- 2008-07-24 AU AU2008279042A patent/AU2008279042B2/en active Active
-
2013
- 2013-10-22 HK HK13111817.3A patent/HK1184196A1/en unknown
-
2016
- 2016-02-08 US US15/017,787 patent/US9939440B2/en active Active
-
2018
- 2018-04-03 US US15/944,148 patent/US20180231552A1/en not_active Abandoned
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090B1 (en) * | 1968-09-24 | 1982-07-20 | ||
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
US5677132A (en) * | 1971-05-20 | 1997-10-14 | Strahilevitz; Meir | Immunological assay reagent package |
US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
US4642285B1 (en) * | 1975-09-29 | 1990-04-17 | Diamedix Corp | |
US4169012A (en) * | 1976-09-24 | 1979-09-25 | Akzona Incorporated | Stabilized peroxidase reagent for enzyme immunoassay |
US5149630A (en) * | 1984-01-26 | 1992-09-22 | Forrest Gordon C | Methods of assay |
US4746631A (en) * | 1985-05-09 | 1988-05-24 | Ultra Diagnostics Corporation | Immunoassay method, device, and test kit |
US4868131A (en) * | 1986-07-11 | 1989-09-19 | Fuji Photo Film Co., Ltd. | Competitive binding immunoassay process |
US7214511B1 (en) * | 1986-10-24 | 2007-05-08 | The Salk Institute For Biological Studies | Hormone receptor compositions and methods |
US6806359B1 (en) * | 1986-10-24 | 2004-10-19 | The Salk Institute For Biological Studies | Hormone receptor compositions and methods |
US5656503A (en) * | 1987-04-27 | 1997-08-12 | Unilever Patent Holdings B.V. | Test device for detecting analytes in biological samples |
US4943522A (en) * | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US5989921A (en) * | 1988-06-27 | 1999-11-23 | Carter Wallace, Inc. | Test device and method for colored particle immunoassay |
US20020090738A1 (en) * | 1988-11-14 | 2002-07-11 | I-Stat Corporation | System and method of microdispensing and arrays of biolayers provided by same |
US5618926A (en) * | 1989-03-10 | 1997-04-08 | Hoffmann-La Roche Inc. | Immunoassay reagents |
US5198367A (en) * | 1989-06-09 | 1993-03-30 | Masuo Aizawa | Homogeneous amperometric immunoassay |
US5766961A (en) * | 1991-01-11 | 1998-06-16 | Quidel Corporation | One-step lateral flow nonbibulous assay |
US5413690A (en) * | 1993-07-23 | 1995-05-09 | Boehringer Mannheim Corporation | Potentiometric biosensor and the method of its use |
US5427912A (en) * | 1993-08-27 | 1995-06-27 | Boehringer Mannheim Corporation | Electrochemical enzymatic complementation immunoassay |
US6110696A (en) * | 1993-08-27 | 2000-08-29 | Roche Diagnostics Corporation | Electrochemical enzyme assay |
US5494831A (en) * | 1993-08-30 | 1996-02-27 | Hughes Aircraft Company | Electrochemical immunosensor system and methods |
US5712172A (en) * | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
US5981298A (en) * | 1995-12-13 | 1999-11-09 | Surmodics, Inc. | Immunoassay device and method |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US6020209A (en) * | 1997-04-28 | 2000-02-01 | The United States Of America As Represented By The Secretary Of The Navy | Microcapillary-based flow-through immunosensor and displacement immunoassay using the same |
US6635434B1 (en) * | 1999-09-17 | 2003-10-21 | Exiqon A/S | Immunoassay for pesticides and their degradation products |
US6478938B1 (en) * | 2000-05-24 | 2002-11-12 | Bio Digit Laboratories Corporation | Electrochemical membrane strip biosensor |
US20040245101A1 (en) * | 2001-08-29 | 2004-12-09 | Itamar Willner | Self-powered biosensor |
US20030143598A1 (en) * | 2001-11-09 | 2003-07-31 | Viswanadham Garimella | Bioconjugate-nanoparticle probes |
US20050130208A1 (en) * | 2002-04-19 | 2005-06-16 | The Trustees Of Columbia University | Displacement assay for detection of small molecules |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
US20050258035A1 (en) * | 2004-05-21 | 2005-11-24 | Agamatrix, Inc. | Electrochemical Cell and Method of Making an Electrochemical Cell |
US20050265094A1 (en) * | 2004-05-30 | 2005-12-01 | Agamatrix, Inc. | Measuring device and methods for use therewith |
US20060160100A1 (en) * | 2005-01-19 | 2006-07-20 | Agency For Science, Technology And Research | Enzymatic electrochemical detection assay using protective monolayer and device therefor |
Cited By (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8439872B2 (en) | 1998-03-30 | 2013-05-14 | Sanofi-Aventis Deutschland Gmbh | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US8016774B2 (en) | 2001-06-12 | 2011-09-13 | Pelikan Technologies, Inc. | Tissue penetration device |
US9694144B2 (en) | 2001-06-12 | 2017-07-04 | Sanofi-Aventis Deutschland Gmbh | Sampling module device and method |
US20060195130A1 (en) * | 2001-06-12 | 2006-08-31 | Dominique Freeman | Tissue penetration device |
US9802007B2 (en) | 2001-06-12 | 2017-10-31 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7981055B2 (en) | 2001-06-12 | 2011-07-19 | Pelikan Technologies, Inc. | Tissue penetration device |
US8206317B2 (en) | 2001-06-12 | 2012-06-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7909775B2 (en) | 2001-06-12 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8845550B2 (en) | 2001-06-12 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8721671B2 (en) | 2001-06-12 | 2014-05-13 | Sanofi-Aventis Deutschland Gmbh | Electric lancet actuator |
US8679033B2 (en) | 2001-06-12 | 2014-03-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7988645B2 (en) | 2001-06-12 | 2011-08-02 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US8641643B2 (en) | 2001-06-12 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Sampling module device and method |
US8622930B2 (en) | 2001-06-12 | 2014-01-07 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9937298B2 (en) | 2001-06-12 | 2018-04-10 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US20070043386A1 (en) * | 2001-06-12 | 2007-02-22 | Dominique Freeman | Tissue penetration device |
US20060195132A1 (en) * | 2001-06-12 | 2006-08-31 | Dominique Freeman | Tissue penetration device |
US20060178688A1 (en) * | 2001-06-12 | 2006-08-10 | Dominique Freeman | Tissue penetration device |
US8382683B2 (en) | 2001-06-12 | 2013-02-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8206319B2 (en) | 2001-06-12 | 2012-06-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8360991B2 (en) | 2001-06-12 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8343075B2 (en) | 2001-06-12 | 2013-01-01 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8123700B2 (en) | 2001-06-12 | 2012-02-28 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8337421B2 (en) | 2001-06-12 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8162853B2 (en) | 2001-06-12 | 2012-04-24 | Pelikan Technologies, Inc. | Tissue penetration device |
US8282577B2 (en) | 2001-06-12 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8216154B2 (en) | 2001-06-12 | 2012-07-10 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8211037B2 (en) | 2001-06-12 | 2012-07-03 | Pelikan Technologies, Inc. | Tissue penetration device |
US9560993B2 (en) | 2001-11-21 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US8430828B2 (en) | 2002-04-19 | 2013-04-30 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8690796B2 (en) | 2002-04-19 | 2014-04-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8197421B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8235915B2 (en) | 2002-04-19 | 2012-08-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US20090192411A1 (en) * | 2002-04-19 | 2009-07-30 | Dominique Freeman | Method and apparatus for penetrating tissue |
US9907502B2 (en) | 2002-04-19 | 2018-03-06 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US8197423B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9839386B2 (en) | 2002-04-19 | 2017-12-12 | Sanofi-Aventis Deustschland Gmbh | Body fluid sampling device with capacitive sensor |
US7875047B2 (en) | 2002-04-19 | 2011-01-25 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8333710B2 (en) | 2002-04-19 | 2012-12-18 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8157748B2 (en) | 2002-04-19 | 2012-04-17 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8337420B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8079960B2 (en) | 2002-04-19 | 2011-12-20 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8062231B2 (en) | 2002-04-19 | 2011-11-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8366637B2 (en) | 2002-04-19 | 2013-02-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8007446B2 (en) | 2002-04-19 | 2011-08-30 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8382682B2 (en) | 2002-04-19 | 2013-02-26 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8388551B2 (en) | 2002-04-19 | 2013-03-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for multi-use body fluid sampling device with sterility barrier release |
US8403864B2 (en) | 2002-04-19 | 2013-03-26 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8414503B2 (en) | 2002-04-19 | 2013-04-09 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7988644B2 (en) | 2002-04-19 | 2011-08-02 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8435190B2 (en) | 2002-04-19 | 2013-05-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8491500B2 (en) | 2002-04-19 | 2013-07-23 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8496601B2 (en) | 2002-04-19 | 2013-07-30 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8556829B2 (en) | 2002-04-19 | 2013-10-15 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8562545B2 (en) | 2002-04-19 | 2013-10-22 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8574168B2 (en) | 2002-04-19 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a multi-use body fluid sampling device with analyte sensing |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US8636673B2 (en) | 2002-04-19 | 2014-01-28 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7959582B2 (en) | 2002-04-19 | 2011-06-14 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7938787B2 (en) | 2002-04-19 | 2011-05-10 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9724021B2 (en) | 2002-04-19 | 2017-08-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7914465B2 (en) | 2002-04-19 | 2011-03-29 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8202231B2 (en) | 2002-04-19 | 2012-06-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7901365B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8808201B2 (en) | 2002-04-19 | 2014-08-19 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for penetrating tissue |
US9498160B2 (en) | 2002-04-19 | 2016-11-22 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US7909777B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US8845549B2 (en) | 2002-04-19 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US8905945B2 (en) | 2002-04-19 | 2014-12-09 | Dominique M. Freeman | Method and apparatus for penetrating tissue |
US7909774B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9339612B2 (en) | 2002-04-19 | 2016-05-17 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9072842B2 (en) | 2002-04-19 | 2015-07-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9089294B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9089678B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9186468B2 (en) | 2002-04-19 | 2015-11-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US9034639B2 (en) | 2002-12-30 | 2015-05-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8262614B2 (en) | 2003-05-30 | 2012-09-11 | Pelikan Technologies, Inc. | Method and apparatus for fluid injection |
US8251921B2 (en) | 2003-06-06 | 2012-08-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US10034628B2 (en) | 2003-06-11 | 2018-07-31 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US8945910B2 (en) | 2003-09-29 | 2015-02-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US8296918B2 (en) | 2003-12-31 | 2012-10-30 | Sanofi-Aventis Deutschland Gmbh | Method of manufacturing a fluid sampling device with improved analyte detecting member configuration |
US9561000B2 (en) | 2003-12-31 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US9261476B2 (en) | 2004-05-20 | 2016-02-16 | Sanofi Sa | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
Also Published As
Publication number | Publication date |
---|---|
EP2174135A1 (en) | 2010-04-14 |
EP2174135A4 (en) | 2010-08-25 |
AU2008279042B2 (en) | 2014-03-13 |
US9939440B2 (en) | 2018-04-10 |
HK1184196A1 (en) | 2014-01-17 |
EP2584044B1 (en) | 2015-04-22 |
CA2694045A1 (en) | 2009-01-29 |
US20160231321A1 (en) | 2016-08-11 |
CN101802612A (en) | 2010-08-11 |
CN106442961A (en) | 2017-02-22 |
EP2584044A2 (en) | 2013-04-24 |
US20180231552A1 (en) | 2018-08-16 |
KR101532064B1 (en) | 2015-06-26 |
AU2008279042A1 (en) | 2009-01-29 |
EP2174135B1 (en) | 2013-01-02 |
KR20100065298A (en) | 2010-06-16 |
CN101802612B (en) | 2016-08-10 |
CA2694045C (en) | 2016-06-21 |
EP2584044A3 (en) | 2013-11-27 |
CN106442961B (en) | 2018-08-14 |
WO2009015291A1 (en) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9939440B2 (en) | Electrochemical analyte detection apparatus and method | |
US9863942B2 (en) | Biosensor apparatus and methods of use | |
Noiphung et al. | Electrochemical detection of glucose from whole blood using paper-based microfluidic devices | |
US9063132B2 (en) | Assay device and method | |
Kergaravat et al. | Electrochemical magneto immunosensor for the detection of anti-TG2 antibody in celiac disease | |
JP5781603B2 (en) | Electrochemical detection method for binding reaction | |
CN102116753A (en) | Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity | |
Song et al. | Electrochemical immunoassay based on indium tin oxide activity toward a alkaline phosphatase | |
JP2008209323A (en) | Enzyme sensor, analysis method and kit using the enzyme sensor | |
US20150226735A1 (en) | Systems and methods for enzyme detection | |
WO2013039455A1 (en) | Amperometric sensor | |
US20210116408A1 (en) | Improved Electrode for Electrochemical Device | |
AU2013204779B2 (en) | Electrochemical analyte detection apparatus and method | |
Nakamura et al. | Current status of homogeneous enzyme immunoassays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AGAMATRIX, INC., NEW HAMPSHIRE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARDING, IAN;IYENGAR, SRIDHAR;WILLIAMS, RICHARD;REEL/FRAME:021592/0712 Effective date: 20080925 |
|
AS | Assignment |
Owner name: MIDCAP FINANCIAL TRUST, MARYLAND Free format text: SECURITY INTEREST;ASSIGNOR:AGAMATRIX, INC.;REEL/FRAME:037405/0728 Effective date: 20151223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: AGAMATRIX, INC., NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FINANCIAL TRUST;REEL/FRAME:044034/0372 Effective date: 20170929 |
|
AS | Assignment |
Owner name: AGAMATRIX, INC., NEW HAMPSHIRE Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 044034 FRAME: 0372. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST;ASSIGNOR:MIDCAP FINANCIAL TRUST;REEL/FRAME:044391/0941 Effective date: 20170929 |